LDE-225 Diphosphate

LDE-225 Diphosphate Structure
CAS No.
1218778-77-8
Chemical Name:
LDE-225 Diphosphate
Synonyms
LDE 225 phosphate;NVP-LDE225;LDE225;Sonidegib phosphate;LDE 225 Diphosphate;LDE-225 Diphosphate;LDE225 (Diphosphate);Erismodegib phosphate;Sonidegib diphosphate;NVP-LDE 225 Diphosphate;ErisModegib Diphosphate
CBNumber:
CB42666648
Molecular Formula:
C26H32F3N3O11P2
Molecular Weight:
681.4885116
MOL File:
1218778-77-8.mol
MSDS File:
SDS
Modify Date:
2024/7/2 8:55:08

LDE-225 Diphosphate Properties

storage temp. Store at -20°C
solubility ≥27.85 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
form White solid.
color White to off-white

LDE-225 Diphosphate Chemical Properties,Uses,Production

Description

Sonidegib phosphate (XXIX), an orally bioavailable, small molecule smoothened (SMO) receptor antagonist developed by Novartis, was approved in 2015 in Switzerland, the U.S., and the EU for the treatment of adult patients with advanced or locally advanced basal cell carcinoma (BCC). BCC is the most frequently diagnosed skin cancer, constituting 80% of all nonmelanoma skin cancers. While most BCCs can be treated through surgery or radiation therapy, some patients (<10%) have more advanced tumors for which surgery may be contraindicated or impractical; treatment options for these patients are limited. SMO, a G-protein coupled receptor-like protein (GPCR), is a key regulator in the hedgehog (Hh) pathway, which is activated in a number of tumors including BCC. In a multicenter clinical trial for sonidegib, an objective response rate of 43% was observed for patients with locally advanced BCC (dosing at 200 mg once daily), with sustained clinically meaningful responses based on an 18-month analysis. Sonidegib joins vismodegib as marketable treatments of BCC. Vismodegib, which was approved in 2012 as a first-in-class SMO receptor antagonist, represented the first Hedgehog signaling pathway targeting agent to gain FDA approval.

Uses

NVP-LDE225 Diphosphate Salt is a potent, selective, and orally bioavailable Smoothened (Hedgehog Signaling Pathway) antagonist.

Definition

ChEBI: A phosphate salt obtained by reaction sonidegib with two equivalent of phosphoric acid. Used for treatment of locally advanced basal cell carcinoma.

LDE-225 Diphosphate Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 75)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
MSN LABORATORIES PRIVATE LTD +91 40 30438600 New Delhi, India 230 58 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29826 58 Inquiry
TargetMol Chemicals Inc. +1-781-999-5354 +1-00000000000 United States 19892 58 Inquiry
InvivoChem +1-708-310-1919 +1-13798911105 United States 6393 58 Inquiry
LEAP CHEM CO., LTD. +86-852-30606658 China 24738 58 Inquiry
ShenZhen Trendseen Biological Technology Co.,Ltd. 13417589054 China 11681 58 Inquiry
Nanjing Fred Technology Co., Ltd +86-25-84696168 +86-15380713688 China 2427 58 Inquiry
Henan Fengda Chemical Co., Ltd +86-371-86557731 +86-13613820652 China 20361 58 Inquiry
Amadis Chemical Company Limited 571-89925085 China 131980 58 Inquiry

LDE-225 Diphosphate Spectrum

LDE225 Diphosphate, >=98% Erismodegib Diphosphate, NVP-LDE225 (diphosphate salt) ErisModegib Diphosphate LDE 225 Diphosphate LDE225 (Diphosphate) LDE-225 Diphosphate NVP-LDE 225 Diphosphate LDE 225 phosphate rel-N-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide phosphate (1:2) Sonidegib phosphate NVP-LDE225;LDE225 NVP-LDE225;LDE225;LDE 225 DIPHOSPHATE;NVP-LDE 225 DIPHOSPHATE;ERISMODEGIB DIPHOSPHATE;LDE-225 DIPHOSPHATE Erismodegib diphosphate (LDE225 diphosphate) Sonidegib (NVP-LDE225) Diphosphate Erismodegib phosphate Sonidegib diphosphate Sonidegib phosphate (NVP-LDE-225, Erismodegib, Odomzo) N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide,phosphoric acid NVP-LDE225 diphosphate,Inhibitor,Smoothened,Sonidegib diphosphate,Smo,inhibit rel-N-(6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide bis(phosphate) NVP-LDE225 DIPHOSPHATE SALT (ERISMODEGIB, SONIDEGIB) rel-N-(6-((2R,6S)-2,6-dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide bis(phosphate) 1218778-77-8 C26H32F3N3O11P2 C26H26F3N3O32H3PO4